Comparative safety and efficacy of tislelizumab-based regimens versus chemotherapy in lung cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Lung cancer is the leading cause of cancer-related mortality worldwide, with its burden expected to rise significantly by 2025. Despite therapeutic advances, survival rates remain low, and comorbidities further complicate management. Economic projections indicate lung cancer will account for the highest share of cancer-related costs through 2050.

Objectives

To evaluate the safety and efficacy of Tislelizumab with or without chemotherapy versus chemotherapy alone in lung cancer by synthesizing available evidence through meta-analysis.

Methodology

This meta-analysis followed PRISMA guidelines and was registered in PROSPERO. A systematic search of PubMed, Embase, Scopus, Cochrane Library, ScienceDirect, and ClinicalTrials.gov was conducted for RCTs comparing T

SUBMITTER: Ullah A 

PROVIDER: S-EPMC12537389 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature